ArticleUrolithiasis2023

Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).

David S Goldfarb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.